# Lymphatic Filariasis: Treatment, Epidemiology & Control
> Explore the epidemiology, drug treatments, and WHO global elimination strategies for Elephantiasis (Lymphatic Filariasis) and Wuchereria bancrofti.

Tags: lymphatic-filariasis, elephantiasis, public-health, epidemiology, wuchereria-bancrofti, infectious-diseases, global-health
## Treatment & Management Options
* **Drug Treatments:** Diethylcarbamazine (DEC) for microfilariae/adult worms, Albendazole (400mg), and Ivermectin (200–400 mcg/kg).
* **Combination Therapies:** Standard 2-drug (DEC + Albendazole) and Triple therapy (Ivermectin + DEC + Albendazole).
* **Morbidity Management:** Lymphedema hygiene/elevation, surgical correction for hydrocele, and antibiotics for acute adenolymphangitis.

## Vaccination & Control Programs
* **Vaccine Status:** No approved vaccine currently exists; experimental trials are ongoing.
* **WHO Global Programme (GPELF):** Goal to eliminate LF by 2030 using Mass Drug Administration (MDA).
* **Success Metrics:** 9.7 billion treatments delivered since 2000, resulting in a 74% decline in global infections.
* **Vector Control:** Use of insecticide-treated bed nets (ITNs) and indoor residual spraying.

## Epidemiology & Global Burden
* **Prevalence:** 120.5M cases globally in 2021 with 1.3B people at risk across 73 countries.
* **Top Affected Countries:** India (33.38M cases), Indonesia (4.26M), and Nigeria (2.85M) account for 71% of the global burden.
* **Australian Context:** Not endemic since 1956; periodic imported cases from PNG and Southeast Asia.

## Pathogen & Disease Profile
* **Causative Agent:** Wuchereria bancrofti (responsible for 90% of cases).
* **Transmission:** Vector-borne via Culex, Anopheles, or Aedes mosquitoes.
* **Lifecycle:** Microfilariae develop into L3 larvae in mosquitoes, then become adult worms in human lymphatics (Females 80–100mm).
---
This presentation was created with [Bobr AI](https://bobr.ai) — an AI presentation generator.